PAR · ALEMG.PA
Euromedis Groupe
€5.55+€0.05 (+0.91%)
Euromedis Groupe’s quoted price sits in the upper half of its reported 52-week range, 9.76% below the high.
Loading market information…
PAR · ALMKT.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Mauna Kea Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 58.36% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Mauna Kea Technologies S.A.’s next earnings report is currently expected on Apr 22, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Mauna Kea Technologies S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Central to its portfolio is Cellvizio, an in vivo cellular imaging platform that delivers real-time data. This innovative system assists medical practitioners in tracking disease evolution, evaluating immediate physiological responses, delineating ambiguous tissue areas, and providing guidance during surgical procedures. Founded in 2000, the company's headquarters are situated in Paris, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€5.55+€0.05 (+0.91%)
Euromedis Groupe’s quoted price sits in the upper half of its reported 52-week range, 9.76% below the high.
€0.85+€0.01 (+1.19%)
Biosynex S.A.’s quoted price sits in the lower half of its reported 52-week range, 45.86% below the high.
€0.14+€0.02 (+16.5%)
TME Pharma N.V.’s quoted price sits in the upper half of its reported 52-week range, 19.93% below the high.
€0.09+€0.00 (+4.0%)
SpineGuard S.A.’s quoted price sits in the lower half of its reported 52-week range, 48.88% below the high.
€0.10-€0.00 (-2.44%)
AMA Corporation Plc’s quoted price sits in the lower half of its reported 52-week range, 50.98% below the high.
€2.20€0.00 (0.0%)
Media Lab S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 45.0% below the high.
€3.74-€0.20 (-5.08%)
Plant Advanced Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 57.79% below the high.
€0.85-€0.07 (-7.61%)
Predilife S.A.’s quoted price sits in the lower half of its reported 52-week range, 78.75% below the high.
